The aim of the project is the development of a specific antibody conjugation platform through the application of ZIP-Inteins® technology, which is based on the use of inteins as a conjugation tool.

The global fight against the COVID-19 pandemic has highlighted the absence of a highly sensitive PoC diagnostic method that directly detects the virus, without prior sample preparation steps, in order to carry out a rapid and accurate diagnosis of the virus on a large scale. As a result, PCR tests have been favoured, with a consequent reduction of diagnostic capacity in absolute terms (fewer tests) due to the intrinsic limitations of the method, coupled with the lack of reagent supply and the saturation of authorised clinical laboratories.

The use of biosensors, especially those based on field effect transistors (FETs), is an important alternative, thanks to their ability to make highly sensitive and instantaneous measurements from small sample amounts.

The aim of the project is to develop a new, low-cost, high-sensitivity and high-specificity HPV diagnostic test that allows rapid detection of the virus in the consultation in which the patient’s sample is taken, minimising dependence on specialised laboratories and specifically trained laboratory staff. This system aims to:

• Facilitate diagnosis and medical decision-making.
• Reduce the HPV diagnosis time to 10-15 minutes.
• Lower the cost of the diagnostic test by up five times its current price.
• Limit reliance on specialised laboratories.
• Diagnose HPV in the consultation in which the patient’s sample is taken.
• Increase the versatility of supramolecular techniques in the design of nanoscopic devices aimed at addressing the clinical needs of patients.

The CoVIg3 project aims to develop a point-of-care rapid test based on lateral flow technology for the qualitative detection of antibodies generated by the humoral response in patients exposed to coronavirus (SARS-Cov-2), whether asymptomatic or having contracted the disease with varying levels of severity. The test will simultaneously carry out a multiplexed analysis of IgA, IgM, and IgG immunoglobulins independently in a single device. The test to be developed will have high sensitivity and specificity levels, a fast response time (15 min), and a low cost.

Secondly, the aim is to analyse the genetic profiles of the Human Leukocyte Antigen (HLA) involved in the response to infections in order to find haplotypes with sensitivity/resistance to infection, as well as possible predictors of the evolution of the disease in its varying levels of severity.

The project aims to develop a pharmacogenomic evaluation system for the treatment of breast cancer with aromatase inhibitors, using a new application designed by ROVI Laboratorios.

Its ultimate goal is the optimisation of drug delivery and release processes.

This project will develop a molecular signature, based on genomics and metabolomics, obtained from liquid biopsies to predict the response to radiotherapy and early relapse in patients with prostate cancer undergoing external radiotherapy (SBRT and IMRT).

Prostate cancer is the second most common cancer among men with 1.28 million cases diagnosed in 2018 worldwide, 88.4% of which were diagnosed in developed countries. It is the sixth leading cause of cancer-related deaths in men, with higher mortality rates in developing countries, and much higher morbidity levels in developed countries thanks to widespread diagnostic methods and early detection. The results obtained in the project will make it possible to predict the response to therapy, as well as to detect early relapse for this type of cancer.